atazanavir   Click here for help

GtoPdb Ligand ID: 11138

Abbreviated name: ATV
Synonyms: BMS-232632 | CGP 73547 | latazanavir | Reyataz® | zrivada
Approved drug PDB Ligand
atazanavir is an approved drug (FDA (2003), EMA (2004))
Compound class: Synthetic organic
Comment: Atazanavir is a human immunodeficiency virus 1 (HIV-1) protease inhibitor (PI) [1].
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: atazanavir

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 13
Hydrogen bond donors 5
Rotatable bonds 22
Topological polar surface area 171.22
Molecular weight 704.39
XLogP 4.55
No. Lipinski's rules broken 2

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COC(=O)N[C@@H](C(C)(C)C)C(=O)NN(Cc1ccc(cc1)c1ccccn1)C[C@@H]([C@H](Cc1ccccc1)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O
Isomeric SMILES COC(=O)N[C@@H](C(C)(C)C)C(=O)NN(Cc1ccc(cc1)c1ccccn1)C[C@@H]([C@H](Cc1ccccc1)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O
InChI InChI=1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1
InChI Key AXRYRYVKAWYZBR-GASGPIRDSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Atazanavir is used as a component of antiretroviral regimens for HIV infections. It can also be administered in cases of potential HIV exposure as postexposure prophylaxis.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Atazanavir inhibits HIV-1 protease, preventing cleavage of viral proteins and resulting in immature non-infectious viral particles. Atazanavir increases the duration of activity of other antiretroviral protease inhibitors.
External links Click here for help